Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Assassi S, Wang X, Chen G, Goldmuntz E, Keyes-Elstein L, Ying J, Wallace PK, Turner J, Zheng WJ, Pascual V, Varga J, Hinchcliff ME, Bellocchi C, McSweeney P, Furst DE, Nash RA, Crofford LJ, Welch B, Pinckney A, Mayes MD, Sullivan KM.

Ann Rheum Dis. 2019 Oct;78(10):1371-1378. doi: 10.1136/annrheumdis-2019-215770. Epub 2019 Aug 7.

PMID:
31391177
2.

Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and Management.

Antin-Ozerkis D, Hinchcliff M.

Clin Chest Med. 2019 Sep;40(3):617-636. doi: 10.1016/j.ccm.2019.05.008. Review.

PMID:
31376896
3.

Towards a new classification of systemic sclerosis.

Hinchcliff M, Mahoney JM.

Nat Rev Rheumatol. 2019 Aug;15(8):456-457. doi: 10.1038/s41584-019-0257-z. No abstract available.

PMID:
31217541
4.

Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.

Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, Chen S, Carns MA, Aren K, Sun J, Koloms K, Lee J, Baral J, Kropski J, Zhao H, Herzog E, Martinez FJ, Moore BB, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya JD, Shah NH, Khatri P.

Lancet Respir Med. 2019 Jun;7(6):497-508. doi: 10.1016/S2213-2600(18)30508-3. Epub 2019 Mar 29.

5.

The importance of technical skills assessment during an airway foreign body removal course.

Hinchcliff M, Kao M, Johnson K.

Int J Pediatr Otorhinolaryngol. 2019 Feb;117:1-5. doi: 10.1016/j.ijporl.2018.11.007. Epub 2018 Nov 9.

PMID:
30579061
6.

Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis.

Reyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, Akbarpour M, Chen CI, Ren Z, Verma R, Abdala-Valencia H, Nam K, Chi M, Han S, Gonzalez-Gonzalez FJ, Soberanes S, Watanabe S, Williams KJN, Flozak AS, Nicholson TT, Morgan VK, Winter DR, Hinchcliff M, Hrusch CL, Guzy RD, Bonham CA, Sperling AI, Bag R, Hamanaka RB, Mutlu GM, Yeldandi AV, Marshall SA, Shilatifard A, Amaral LAN, Perlman H, Sznajder JI, Argento AC, Gillespie CT, Dematte J, Jain M, Singer BD, Ridge KM, Lam AP, Bharat A, Bhorade SM, Gottardi CJ, Budinger GRS, Misharin AV.

Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536. doi: 10.1164/rccm.201712-2410OC.

7.

Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.

Showalter K, Hoffmann A, Rouleau G, Aaby D, Lee J, Richardson C, Dematte J, Agrawal R, Chang RW, Hinchcliff M.

J Rheumatol. 2018 Nov;45(11):1572-1576. doi: 10.3899/jrheum.171362. Epub 2018 Oct 1.

8.

Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.

Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD.

J Rheumatol. 2019 Feb;46(2):176-183. doi: 10.3899/jrheum.180018. Epub 2018 Oct 1.

PMID:
30275260
9.

The novel adipokine C1q-TNF related protein 9 (CTRP9) is elevated in systemic sclerosis-associated interstitial lung disease.

Korman B, Alejo R, Sudhakar D, Hinchcliff M, Agrawal R, Varga J, Marangoni RG.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):184-185. Epub 2018 Aug 28. No abstract available.

10.

Normal Values of Esophageal Distensibility and Distension-Induced Contractility Measured by Functional Luminal Imaging Probe Panometry.

Carlson DA, Kou W, Lin Z, Hinchcliff M, Thakrar A, Falmagne S, Prescott J, Dorian E, Kahrilas PJ, Pandolfino JE.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):674-681.e1. doi: 10.1016/j.cgh.2018.07.042. Epub 2018 Aug 3.

PMID:
30081222
11.

The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.

Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD; SPIN Investigators.

Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631. doi: 10.1093/rheumatology/key139.

PMID:
29868924
12.

Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis.

Lee DC, Hinchcliff ME, Sarnari R, Stark MM, Lee J, Koloms K, Hoffmann A, Carns M, Thakrar A, Aren K, Varga J, Aquino A, Carr JC, Benefield BC, Shah SJ.

J Scleroderma Relat Disord. 2018 Jun;3(2):159-169. doi: 10.1177/2397198318762888. Epub 2018 Apr 12.

13.

Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.

Mandelin AM 2nd, Homan PJ, Shaffer AM, Cuda CM, Dominguez ST, Bacalao E, Carns M, Hinchcliff M, Lee J, Aren K, Thakrar A, Montgomery AB, Bridges SL Jr, Bathon JM, Atkinson JP, Fox DA, Matteson EL, Buckley CD, Pitzalis C, Parks D, Hughes LB, Geraldino-Pardilla L, Ike R, Phillips K, Wright K, Filer A, Kelly S, Ruderman EM, Morgan V, Abdala-Valencia H, Misharin AV, Budinger GS, Bartom ET, Pope RM, Perlman H, Winter DR.

Arthritis Rheumatol. 2018 Jun;70(6):841-854. doi: 10.1002/art.40453. Epub 2018 May 3.

14.

Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.

Hinchcliff M, Toledo DM, Taroni JN, Wood TA, Franks JM, Ball MS, Hoffmann A, Amin SM, Tan AU, Tom K, Nesbeth Y, Lee J, Ma M, Aren K, Carns MA, Pioli PA, Whitfield ML.

J Invest Dermatol. 2018 Jun;138(6):1301-1310. doi: 10.1016/j.jid.2018.01.006. Epub 2018 Jan 31.

15.

Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Stern EK, Carlson DA, Falmagne S, Hoffmann AD, Carns M, Pandolfino JE, Hinchcliff M, Brenner DM.

Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13247. Epub 2017 Nov 6.

16.

Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.

Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, Chen CI, Anekalla KR, Joshi N, Williams KJN, Abdala-Valencia H, Yacoub TJ, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Gates K, Lam AP, Nicholson TT, Homan PJ, Soberanes S, Dominguez S, Morgan VK, Saber R, Shaffer A, Hinchcliff M, Marshall SA, Bharat A, Berdnikovs S, Bhorade SM, Bartom ET, Morimoto RI, Balch WE, Sznajder JI, Chandel NS, Mutlu GM, Jain M, Gottardi CJ, Singer BD, Ridge KM, Bagheri N, Shilatifard A, Budinger GRS, Perlman H.

J Exp Med. 2017 Aug 7;214(8):2387-2404. doi: 10.1084/jem.20162152. Epub 2017 Jul 10.

17.

Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis.

Korman BD, Marangoni RG, Hinchcliff M, Shah SJ, Carns M, Hoffmann A, Ramsey-Goldman R, Varga J.

Arthritis Rheumatol. 2017 Oct;69(10):2062-2068. doi: 10.1002/art.40193.

18.

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.

Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML.

Genome Med. 2017 Mar 23;9(1):27. doi: 10.1186/s13073-017-0417-1.

19.

Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort.

Gordon JK, Girish G, Berrocal VJ, Zhang M, Hatzis C, Assassi S, Bernstein EJ, Domsic RT, Hant FN, Hinchcliff M, Schiopu E, Steen VD, Frech TM, Khanna D.

J Rheumatol. 2017 Jun;44(6):791-794. doi: 10.3899/jrheum.160654. Epub 2017 Mar 15.

20.

Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.

Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, Cheung P, Kuo A, Valenzuela A, Haemel A, Wolters PJ, Gordon J, Spiera R, Assassi S, Boin F, Chung L, Fiorentino D, Utz PJ, Whitfield ML, Khatri P.

JCI Insight. 2016 Dec 22;1(21):e89073. doi: 10.1172/jci.insight.89073.

21.

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.

Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):106-113. Epub 2016 Nov 10.

PMID:
27908301
22.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

23.

Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study.

Valenzuela A, Baron M; Canadian Scleroderma Research Group, Herrick AL, Proudman S, Stevens W; Australian Scleroderma Interest Group, Rodriguez-Reyna TS, Vacca A, Medsger TA Jr, Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L.

Semin Arthritis Rheum. 2016 Dec;46(3):344-349. doi: 10.1016/j.semarthrit.2016.05.008. Epub 2016 Jun 2.

24.

Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate.

Hinchcliff ME, Lomasney J, Johnson JA, Varga J.

Rheumatology (Oxford). 2016 Oct;55(10):1916-8. doi: 10.1093/rheumatology/kew245. Epub 2016 Jun 23. Review. No abstract available.

25.

Comment on "Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study".

Hoffmann A, Lee J, Ma M, Agrawal R, Chang RW, Richardson C, Hinchcliff M, Showalter K.

Semin Arthritis Rheum. 2016 Oct;46(2):e11-e12. doi: 10.1016/j.semarthrit.2016.04.006. Epub 2016 May 6. No abstract available.

26.

Tenascin-C drives persistence of organ fibrosis.

Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Budinger GR, Raparia K, Tamaki Z, Varga J.

Nat Commun. 2016 Jun 3;7:11703. doi: 10.1038/ncomms11703.

27.

Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis.

Carlson DA, Crowell MD, Kimmel JN, Patel A, Gyawali CP, Hinchcliff M, Griffing WL, Pandolfino JE, Vela MF.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1502-6. doi: 10.1016/j.cgh.2016.03.039. Epub 2016 Apr 5.

28.

Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.

Richardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, Cuttica MJ, Dematte JD, Chang RW, Hinchcliff ME.

Semin Arthritis Rheum. 2016 Aug;46(1):109-14. doi: 10.1016/j.semarthrit.2016.02.004. Epub 2016 Feb 26.

29.

The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters.

Kimmel JN, Carlson DA, Hinchcliff M, Carns MA, Aren KA, Lee J, Pandolfino JE.

Neurogastroenterol Motil. 2016 Aug;28(8):1157-65. doi: 10.1111/nmo.12813. Epub 2016 Feb 27.

30.

The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis.

Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R.

Rheumatology (Oxford). 2016 May;55(5):911-7. doi: 10.1093/rheumatology/kew003. Epub 2016 Feb 15.

31.

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients.

Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD.

Arthritis Res Ther. 2016 Jan 20;18:20. doi: 10.1186/s13075-016-0923-3.

32.

Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures.

Taroni JN, Martyanov V, Huang CC, Mahoney JM, Hirano I, Shetuni B, Yang GY, Brenner D, Jung B, Wood TA, Bhattacharyya S, Almagor O, Lee J, Sirajuddin A, Varga J, Chang RW, Whitfield ML, Hinchcliff M.

Arthritis Res Ther. 2015 Jul 29;17:194. doi: 10.1186/s13075-015-0695-1.

33.

Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.

Hinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, Steen V, Chung L; PHAROS Investigators.

Semin Arthritis Rheum. 2015 Dec;45(3):309-14. doi: 10.1016/j.semarthrit.2015.06.011. Epub 2015 Jun 19.

34.

Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report.

Frech TM, Revelo MP, Ryan JJ, Shah AA, Gordon J, Domsic R, Hant F, Assassi S, Shanmugam VK, Hinchcliff M, Steen V, Khanna D, Bernstein EJ, Cox J, Luem N, Drakos S.

J Med Case Rep. 2015 Jun 10;9:136. doi: 10.1186/s13256-015-0587-7.

35.

A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis.

Marangoni RG, Korman BD, Allanore Y, Dieude P, Armstrong LL, Rzhetskaya M, Hinchcliff M, Carns M, Podlusky S, Shah SJ, Ruiz B, Hachulla E, Tiev K, Cracowski JL, Varga J, Hayes MG.

Arthritis Res Ther. 2015 May 19;17:128. doi: 10.1186/s13075-015-0641-2.

36.

The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.

Wei J, Ghosh AK, Chu H, Fang F, Hinchcliff ME, Wang J, Marangoni RG, Varga J.

Arthritis Rheumatol. 2015 May;67(5):1323-34. doi: 10.1002/art.39061.

37.

Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.

Lakota K, Carns M, Podlusky S, Mrak-Poljsak K, Hinchcliff M, Lee J, Tomsic M, Sodin-Semrl S, Varga J.

PLoS One. 2015 Jan 28;10(1):e0110820. doi: 10.1371/journal.pone.0110820. eCollection 2015.

38.

Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts.

Johnson ME, Mahoney JM, Taroni J, Sargent JL, Marmarelis E, Wu MR, Varga J, Hinchcliff ME, Whitfield ML.

PLoS One. 2015 Jan 21;10(1):e0114017. doi: 10.1371/journal.pone.0114017. eCollection 2015.

39.

Antinuclear antibody-negative systemic sclerosis.

Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD.

Semin Arthritis Rheum. 2015 Jun;44(6):680-6. doi: 10.1016/j.semarthrit.2014.11.006. Epub 2014 Nov 28.

40.

Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms.

Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, Hinchcliff ME, Whitfield ML.

PLoS Comput Biol. 2015 Jan 8;11(1):e1004005. doi: 10.1371/journal.pcbi.1004005. eCollection 2015 Jan. Erratum in: PLoS Comput Biol. 2015 Mar;11(3):e1004133.

41.

Advances in the evaluation and management of esophageal disease of systemic sclerosis.

Carlson DA, Hinchcliff M, Pandolfino JE.

Curr Rheumatol Rep. 2015 Jan;17(1):475. doi: 10.1007/s11926-014-0475-y. Review.

42.

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Fischer A, Swigris JJ, Bolster MB, Chung L, Csuka ME, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers LK, Gomberg-Maitland M, Mathai SC, Simms R, Steen VD.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-109-14. Epub 2014 Nov 4.

PMID:
25372796
43.

Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis.

Hinchcliff ME, Beaumont JL, Carns MA, Podlusky S, Thavarajah K, Varga J, Cella D, Chang RW.

J Rheumatol. 2015 Jan;42(1):64-72. doi: 10.3899/jrheum.140143. Epub 2014 Nov 1.

44.

FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.

Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, White ES, Varga J.

Sci Transl Med. 2014 Apr 16;6(232):232ra50. doi: 10.1126/scitranslmed.3008264.

45.

Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.

Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD.

Semin Arthritis Rheum. 2014 Aug;44(1):55-62. doi: 10.1016/j.semarthrit.2014.03.002. Epub 2014 Mar 5.

PMID:
24709277
46.

Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?

Varga J, Hinchcliff M.

Nat Rev Rheumatol. 2014 Apr;10(4):200-2. doi: 10.1038/nrrheum.2014.22. Epub 2014 Feb 18.

47.

Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis.

Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Tan FK, Arnett FC, Reveille JD, Guerra S, Teruel M, Carmona FD, Gregersen PK, Lee AT, López-Isac E, Ochoa E, Carreira P, Simeón CP, Castellví I, González-Gay MÁ; Spanish Scleroderma Group, Zhernakova A, Padyukov L, Alarcón-Riquelme M, Wijmenga C, Brown M, Beretta L, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, Schuerwegh AJ, Hesselstrand R, Nordin A, Airó P, Lunardi C, Shiels P, van Laar JM, Herrick A, Worthington J, Denton C, Wigley FM, Hummers LK, Varga J, Hinchcliff ME, Baron M, Hudson M, Pope JE, Furst DE, Khanna D, Phillips K, Schiopu E, Segal BM, Molitor JA, Silver RM, Steen VD, Simms RW, Lafyatis RA, Fessler BJ, Frech TM, Alkassab F, Docherty P, Kaminska E, Khalidi N, Jones HN, Markland J, Robinson D, Broen J, Radstake TR, Fonseca C, Koeleman BP, Martin J.

Am J Hum Genet. 2014 Jan 2;94(1):47-61. doi: 10.1016/j.ajhg.2013.12.002.

48.

Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.

Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):489-95. doi: 10.1002/acr.22121.

49.

Treatment of early diffuse systemic sclerosis skin disease.

Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):166-71. Epub 2013 Jul 23. Review.

50.

Early growth response 3 (Egr-3) is induced by transforming growth factor-β and regulates fibrogenic responses.

Fang F, Shangguan AJ, Kelly K, Wei J, Gruner K, Ye B, Wang W, Bhattacharyya S, Hinchcliff ME, Tourtellotte WG, Varga J.

Am J Pathol. 2013 Oct;183(4):1197-1208. doi: 10.1016/j.ajpath.2013.06.016. Epub 2013 Jul 30.

Supplemental Content

Loading ...
Support Center